Peri-procedural management of patients on oral anticoagulants requires individualized decision-making, with emerging evidence suggesting bridging therapy may increase bleeding risk without reducing thrombosis.
No takes yet. Share an insight, caveat, or question.
Clinicians should individualize thrombosis-bleeding risk assessment for peri-procedural decisions; leaves open validated tools for DOAC patients.
Paul R. Daniels (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: